Clinical trials: Sunitinib
Papillary Renal Cell Carcinoma
Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC
A clinical trial to compare the effectiveness of savolitinib plus durvalumab versus sunitinib in MET-driven (hepatocyte growth factor receptor), unresectable and locally advanced or metastatic PRCC (Papillary Renal Cell…
- Trial name
- SAMETA (NCT05043090)
- Testing
- savolitinib, durvalumab, sunitinib
- Where
- 139 sites in United States, Argentina and 23 more
- Volunteers
- 148 people
- Sponsor
- AstraZeneca
Carcinoma Renal Cells
Sunitinib in Patients With Renal Cells Carcinoma Metastasic or Locally Avanced in Patients Not Candidates to Curative Previous Nefrectomy
The purpose of this trial is to determinate the efficacy of Sunitinib in patients with renal cells carcinoma metastasic or locally avanced in patints not candidates to inicial curative nefrectomy.
- Trial name
- SOGUG/0107 (NCT00663559)
- Testing
- Sunitinib
- Where
- 7 sites in Spain
- Volunteers
- 59 people
- Sponsor
- Spanish Oncology Genito-Urinary Group
Metastatic Renal Cell Carcinoma
Post Marketing Surveillance On The Safety And Tolerability Of Sunitinib Malate (Sutent) For Filipino Patients
The primary purpose is to monitor the safety and tolerability and effectiveness of sunitinib malate in the treatment of patients with metastatic renal cell carcinoma and gastrointestinal stromal tumor among filipino patients in…
- Trial name
- NCT01073644
- Testing
- Sunitinib malate
- Where
- 2 sites in Philippines
- Volunteers
- 3 people
- Sponsor
- Pfizer
Gastrointestinal Stromal Tumors
Treatment Patterns in Gastrointestinal Stromal Tumors in the Community Oncology Setting
This is a retrospective medical record abstraction to evaluate the patterns of care for Gastrointestinal stromal tumors (GIST) in the community setting.
- Trial name
- NCT00877045
- Where
- 5 sites in United States
- Volunteers
- 200 people
- Sponsor
- SCRI Development Innovations, LLC
Unspecified Adult Solid Tumor, Protocol Specific
Kidney and Blood Pressure Changes in Patients Receiving Bevacizumab, Aflibercept, Sunitinib, or Cediranib for Cancer
This research study is looking at kidney and blood pressure changes in patients receiving bevacizumab, aflibercept, sunitinib, or cediranib for cancer.
- Trial name
- NCI 8076 (NCT00691730)
- Testing
- laboratory biomarker analysis
- Where
- 4 sites in Canada
- Volunteers
- 52 people
- Sponsor
- University Health Network, Toronto
Kidney Cancer, Metastatic Cancer
Sunitinib in Treating Patients With Kidney Cancer That Has Spread to the Brain
RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00814021
- Testing
- sunitinib malate
- Where
- France
- Volunteers
- 21 people
- Sponsor
- Institut Claudius Regaud
Metastatic Renal Cell Carcinoma
Clinical Outcomes for Patients With Renal Cell Carcinoma Who Received First-Line Sunitinib
This is a retrospective, longitudinal cohort study that assessed clinical outcomes of patients with metastatic renal cell carcinoma (mRCC) who received sunitinib as first-line treatment.
- Trial name
- NCT04076787
- Testing
- Sunitinib
- Where
- Canada
- Volunteers
- 1,769 people
- Sponsor
- Pfizer
Renal Cell Carcinoma
Arterial Spin Labeling Blood Flow MRI for Evaluation of Response to Antiangiogenic and Targeted Therapies of Renal Cell Carcinoma (RCC)
The purpose of this study is to assess magnetic resonance imaging (MRI) as a tool to track tumor growth for renal cell carcinoma while the participant is receiving clinical treatment therapy with sunitinib or pazopanib.
- Trial name
- NCT00749320
- Testing
- Arterial Spin Labeling Magnetic Resonance Imaging
- Where
- 2 sites in United States
- Volunteers
- 32 people
- Sponsor
- Beth Israel Deaconess Medical Center
Gastric Adenocarcinoma, Barrett Esophagus
Efficacy and Safety of Sunitinib in Metastatic Gastric Cancer
This trial will be conducted to evaluate the efficacy, safety, and tolerability of sunitinib (sunitinib-malate) as a second-line palliative therapy in metastatic gastric cancer.
- Trial name
- NCT00411151
- Testing
- Sunitinib-Malate
- Where
- 12 sites in Germany
- Volunteers
- 52 people
- Sponsor
- Johannes Gutenberg University Mainz
Lung Cancer, Adenocarcinoma
Phase II Trial of Sunitinib in BAC or Never-Smokers With Any Lung Adenocarcinoma
This is an open-label study of a new oral drug for advanced stage (IIIB or IV) lung cancer. The cancer must be EITHER bronchoalveolar carcinoma (BAC) type, or if the patient is a never-smoker (less than 100 cigarettes lifetime)…
- Trial name
- NCT00430261
- Testing
- sunitinib
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Swedish Medical Center
Solid Tumors, Breast Cancer
Docetaxel With or Without Low-dose, Short Course Sunitinib in Refractory Solid Tumors
This study aims to find out whether the effect of docetaxel chemotherapy may be improved by combining it with another anti-cancer drug called sunitinib, which stops blood vessels from growing (anti-angiogenic agent).
- Conditions
- Solid Tumors, Breast Cancer, Non-small Cell Lung Cancer, Prostate Cancer
- Trial name
- NCT01803503
- Testing
- Docetaxel, Sunitinib
- Where
- 2 sites in Singapore
- Volunteers
- 80 people
- Sponsor
- National University Hospital, Singapore
Metastatic/Advanced Renal Cell Carcinoma
Evaluation Of The Impact Of A Call Center In Management Of Metastatic And/Or Advanced Renal Cell Carcinoma Patients Treated With Sunitinib (Sutent) In First Line
100 patients with metastatic and/or advanced renal cell carcinoma treated with sunitinib (Sutent) will be inclued and followed with standard care plus a call center Principal assumption : the proportion of patients presenting…
- Trial name
- RENACALL (NCT02187042)
- Testing
- Best supportive care, call center
- Where
- 13 sites in France
- Volunteers
- 70 people
- Sponsor
- Pfizer
Solid Tumors, Breast Cancer
A Study To Find The Best Doses Of SU011248 (Sunitinib) And Capecitabine When These Drugs Are Administered Together
This study assesses the maximum tolerated dose, overall safety and antitumor activity of SU011248 in combination with capecitabine in patients with advanced solid tumors
- Conditions
- Solid Tumors, Breast Cancer, Neoplasms
- Trial name
- NCT00618124
- Testing
- SU011248; Capecitabine
- Where
- 3 sites in United States
- Volunteers
- 77 people
- Sponsor
- Pfizer
Central Nervous System Metastases, Childhood Central Nervous System Choriocarcinoma
Sunitinib in Treating Young Patients With Refractory Solid Tumors
This phase I trial is studying the side effects and best dose of sunitinib in treating young patients with refractory solid tumors.
- Conditions
- Central Nervous System Metastases, Childhood Central Nervous System Choriocarcinoma, Childhood Central Nervous System Embryonal Tumor, Childhood Central Nervous System Germ Cell Tumor
- Trial name
- NCT00387920
- Testing
- sunitinib malate, pharmacological study, dynamic contrast-enhanced magnetic resonance imaging
- Where
- 17 sites in United States, Canada
- Volunteers
- 35 people
- Sponsor
- National Cancer Institute (NCI)
Renal Cell Carcinoma, Metastatic, Renal Cell Cancer, Recurrent
Role of PRoactivE Coaching on PAtient REported Outcome in Advanced or Metastatic RCC Treated With Sunitinib or a Combination of Pembrolizumab + Axitinib or Avelumab + Axitinib in First Line Therapy
The primary objective of the trial is to determine the effect of a 24-week concomitant coaching on patient reported outcomes of patients receiving standard treatment for mRCC with sunitinib or a combination of pembrolizumab +…
- Trial name
- PREPARE (NCT03013946)
- Testing
- Concomitant coaching
- Where
- 22 sites in Germany
- Volunteers
- 121 people
- Sponsor
- AIO-Studien-gGmbH
Ascites
Trial of Sunitinib for Refractory Malignant Ascites
The study is to see whether treatment with Sunitinib decreases the accumulation of ascites in patients with refractory malignant ascites.
- Trial name
- NCT00796861
- Testing
- Sunitinib
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Milton S. Hershey Medical Center
Carcinoma, Renal Cell
Incidence, Prevalence, and Symptom Burden Associated With Advanced Renal Cell Carcinoma in Commercially Insured Population (Pharmetrics)
Information on the prevalence of advanced/metastatic renal cell carcinoma and its symptom burden is limited in commercially insured adult patients.
- Trial name
- NCT01381601
- Testing
- Targeted agents indicated in management of advanced/metastatic RCC (sunitinib, sorafenib, bevacizumab, and pazopanib)
- Volunteers
- 1 people
- Sponsor
- GlaxoSmithKline
Gastrointestinal Stromal Tumors (GISTs)
Phase II Study of Regorafenib Continuous Dosing of Regorafenib in Patients With GISTs
Randomized, placebo-controlled, phase III study of regorafenib 160 mg once daily on intermittent dosing schedule of 3 weeks on treatment followed by 1 weeks off demonstrated the significant benefit of regorafenib in terms of PFS…
- Trial name
- NCT02889328
- Testing
- Regorafenib
- Where
- South Korea
- Volunteers
- 25 people
- Sponsor
- Asan Medical Center
Renal Cell Carcinoma
Sunitinib Intake Conditions in the Treatment of Patients With Renal Cell Carcinoma
This non-interventional study includes patients with advanced renal cell carcinoma who are treated with Sunitinib alone or combined with other systemic therapies.
- Trial name
- NCT01441661
- Where
- 2 sites in China
- Volunteers
- 400 people
- Sponsor
- Cancer Foundation, China
Esophageal Cancer, Gastric Cancer
Sunitinib, Irinotecan, Fluorouracil, and Leucovorin In Treating Patients With Advanced Stomach Cancer or Gastroesophageal Cancer
RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00524186
- Testing
- fluorouracil, irinotecan hydrochloride, leucovorin calcium
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Roswell Park Cancer Institute